Advanced search
Publication Cover
Acta Oncologica Volume 41, 2002 - Issue 7-8
Journal homepage
252
Views
23
CrossRef citations to date
0
Altmetric
Research Article

Patients above Sixty Years Lymphoma Treated with a New Strategy of Age with Hodgkin's

Gunilla Enblad From the Departments of Oncology, Radiology and Clinical Immunology (G. Enblad, B. Glimelius) and Genetics and Pathology (C. Sundstrom), Uppsala University Hospital and the Department of Oncology (A. Gustavsson), Lund University Hospital, Lund, Sweden
,
Anita Gustavsson From the Departments of Oncology, Radiology and Clinical Immunology (G. Enblad, B. Glimelius) and Genetics and Pathology (C. Sundstrom), Uppsala University Hospital and the Department of Oncology (A. Gustavsson), Lund University Hospital, Lund, Sweden
,
Christer Sundström From the Departments of Oncology, Radiology and Clinical Immunology (G. Enblad, B. Glimelius) and Genetics and Pathology (C. Sundstrom), Uppsala University Hospital and the Department of Oncology (A. Gustavsson), Lund University Hospital, Lund, Sweden
&
Bengt Glimelius From the Departments of Oncology, Radiology and Clinical Immunology (G. Enblad, B. Glimelius) and Genetics and Pathology (C. Sundstrom), Uppsala University Hospital and the Department of Oncology (A. Gustavsson), Lund University Hospital, Lund, Sweden
Pages 659-667 | Published online: 08 Jul 2009

  • Guinee VF, Giacco GG, Durand M, et al. The prognosis of Hodgkin's disease in older adults. J Clin Oncol 1991; 9:947-53.
  • Vaughan Hudson B, MacLennan KA, Easterling MJ, et al. The prognostic significance of age in Hodgkin's disease: examination of 1500 patients (BNLI report no. 23). Clin Radiol 1983; 34: 503-6.
  • Erdkamp FL, Breed WP, Bosch LJ, Winjen JT, Blijham GB. Hodgkin's disease in the elderly. Cancer 1992; 70: 830-4.
  • Walker A, Schoenfeld ER, Lowman JT, et al. Survival of the older patient compared with the younger patient with Hodgkin's disease. Cancer 1990; 65: 1635-40.
  • Glimelius B, Enblad G, Kälkner M, et al. Treatment of Hodgkin's disease: the Swedish National Care Program experience. Leuk Lymphoma 1996; 21: 71-8.
  • Gustavsso n A. Hodgkin's disease of the elderly. A different disease? Hematol Oncol 1993; 11 (Suppl 1): 73-7.
  • Sextro M. Difference in clinical presentation and course between adult patients with Hodgkin's disease older and younger than 60 years. Am Soc of Hematol, Dec 1996. Blood 1997; 88 (Suppl 1): 227A (Abstr).
  • Illes A, Vadasz G, Gergely L, Szegedi G. Hodgkin's disease in the elderly: a single institution retrospective study of 40 patients aged 65 or over. Haematologia (Budap) 2000; 30: 263-9.
  • Enblad G, Glimelius B, Sundström C. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population based study. Ann Oncol 1991; 2: 297-302.
  • Brandt L, Kim by E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in Hodgkin's disease. Acta Oncol 2001; 40: 185-97.
  • Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiological characteristics in international data. Int J Cancer 1997; 70: 375-82.
  • Jarret AF, Armstrong AA, Alexander E. Epidemiology of EBV and Hodgkin's lymphoma. Ann Oncol 1996; 7 (Suppl 4): 5-10.
  • Niedobitek G. The role of Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Ann Oncol 1996; 7 (Suppl 4): 11 -7.
  • Enblad G, Sandvej K, Sundström C, Pallesen G, Glimelius B. The proportion of EBV-positive Hodgkin's disease in an unselected population. Acta Oncol 1999; 38: 425-9.
  • Naresh KN, Johnson J, Srinivas V, et al. Epstein-Barr virus association in classical Hodgkin's disease provides survival advantage to patients and correlates with higher expression of proliferation markers in Reed-Sternberg cells. Ann Oncol 2000; 11: 91-6.
  • Morente MM, Piris MA, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki 67 proliferation index, and absence of Epstein-Barr virus latent membrane protein 1 expression. Blood 1997; 90: 2429-36.
  • Enblad G, Sundström C, Glimelius B. Immunohistochemical characteristics of Hodgkin and Reed-Sternberg cells in relation to age and clinical outcome. Histopathology 1993; 22: 535-41.
  • Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-14.
  • Franklin J, Paulus U, Lieberz, et al. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? Ann Oncol 2000; 11: 617-623.
  • Amini R-M, Enblad G, Gustavsson A, et al. Treatment outcome in patients younger than 60 years of advanced stages (IIB-IV) Hodgkin's disease. Eur J Haematol 2000; 65:379-89.
  • Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 85:1361 92.
  • Carbone PP, Kaplan HS, et al. Report on the committee on Hodgkin's disease staging. Cancer Res 1971; 31: 1960-1.
  • Levis A, Depaoli L, Bertini M, et al. Results of a low aggressive chemotherapy regimen (ChlVP/CEB) in elderly Hodgkin's disease patients. Haematologica 1996; 81: 450-6.
  • Zinzani PL, Magagnoli M, Bendandi M, et al. Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease. Haematologia 2000; 85: 729-32.
  • Nygren P, Glimelius B. The Swedish council of technology assessment in health care (SBU) report on cancer chemotherapy-project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation. Acta Oncol 2001; 40: 155-65.
  • Voog E, Warzocha K, Moullet I, et al. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumour necrosis factor ligand-receptor system. J Clin Oncol 2000; 18: 325-31.
  • Vener C, Guffanti A, Pomati M, et al. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease. Leuk Lymphoma 2000; 37: 333-9.
  • Tullgren O, Grimfors G, Holm G, et al. M. lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. Cancer 1991; 68: 768-75.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.